Oral systemic therapy: Not all "win-win"

被引：14

作者：

Bhattacharyya, G. S. ^{[1
]}

机构：

[1] AMRI Hosp, Dept Med Oncol & Clin Hematol, Orchid Nursing Home, Gariahat Rd,CIT Rd, Kolkata, India

来源：

INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY | 2010年 / 31卷 / 01期

关键词：

D O I：

10.4103/0971-5851.68844

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1 / 3

页数：3

共 10 条

[1] Drug-drug interactions in oncology: Why are they important and can they be minimized? [J].

Blower, P ;

de Wit, R ;

Goodin, S ;

Aapro, M .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 55 (02) :117-142

[2]

Borner M, 2000, P AN M AM SOC CLIN, V19, P741

[3] Gender differences in p-glycoprotein:: Drug toxicity and response [J].

Davis, M .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6439-6440

[4] Pharmacogenetics of capecitabine in advanced breast cancer patients [J].

Largillier, Rmy ;

Etienne-Grimaldi, Marie-Christine ;

Formento, Jean-Louis ;

Ciccolin, Joseph ;

Nebbia, Jean-Francois ;

Ginot, Aurelie ;

Francoual, Mireille ;

Renee, Nicole ;

Ferrero, Jean-Marc ;

Foa, Cyril ;

Namer, Moise ;

Lacarelle, Bruno ;

Milano, Gerard .

CLINICAL CANCER RESEARCH, 2006, 12 (18) :5496-5502

[5] Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-06 [J].

Lembersky, BC ;

Wieand, HS ;

Petrelli, NJ ;

O'Connell, MJ ;

Colangelo, LH ;

Smith, RE ;

Seay, TE ;

Giguere, JK ;

Marshall, ME ;

Jacobs, AD ;

Colman, LK ;

Soran, A ;

Yothers, G ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2059-2064

[6] Patient preferences for oral versus intravenous palliative chemotherapy [J].

Liu, G ;

Franssen, E ;

Fitch, MI ;

Warner, E .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :110-115

[7] Pharmacokinetic optimisation of treatment with oral etoposide [J].

Toffoli, G ;

Corona, G ;

Basso, B ;

Boiocchi, M .

CLINICAL PHARMACOKINETICS, 2004, 43 (07) :441-466

[8] Capecitabine as adjuvant treatment for stage III colon cancer [J].

Twelves, C ;

Wong, A ;

Nowacki, MP ;

Abt, M ;

Burris, H ;

Carrato, A ;

Cassidy, J ;

Cervantes, A ;

Fagerberg, J ;

Georgoulias, V ;

Husseini, F ;

Jodrell, D ;

Koralewski, P ;

Kröning, H ;

Maroun, J ;

Marschner, N ;

McKendrick, J ;

Pawlicki, M ;

Rosso, R ;

Schüller, J ;

Seitz, JF ;

Stabuc, B ;

Tujakowski, J ;

Van Hazel, G ;

Zaluski, J ;

Scheithauer, W .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26) :2696-2704

[9] Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials [J].

Van Cutsem, E ;

Hoff, PM ;

Harper, P ;

Bukowski, RM ;

Cunningham, D ;

Dufour, P ;

Graeven, U ;

Lokich, J ;

Madajewicz, S ;

Maroun, JA ;

Marshall, JL ;

Mitchell, EP ;

Perez-Manga, G ;

Rougier, P ;

Schmiegel, W ;

Schoelmerich, J ;

Sobrero, A ;

Schilsky, RL .

BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1190-1197

[10] Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument [J].

Ward, WL ;

Hahn, EA ;

Mo, F ;

Hernandez, L ;

Tulsky, DS ;

Cella, D .

QUALITY OF LIFE RESEARCH, 1999, 8 (03) :181-195

← 1 →